{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Isoform selective inhibitors", "MMGBSA", "Molecular docking", "Molecular dynamics", "Phosphatidylinositol 3-kinase"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35438328", "DateCompleted": {"Year": "2022", "Month": "04", "Day": "21"}, "DateRevised": {"Year": "2022", "Month": "05", "Day": "06"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "04", "Day": "19"}], "Language": ["eng"], "ELocationID": ["10.1007/s00894-022-05096-w"], "Journal": {"ISSN": "0948-5023", "JournalIssue": {"Volume": "28", "Issue": "5", "PubDate": {"Year": "2022", "Month": "Apr", "Day": "19"}}, "Title": "Journal of molecular modeling", "ISOAbbreviation": "J Mol Model"}, "ArticleTitle": "Computational study reveals substituted benzimidazole derivatives' binding selectivity to PI3K\u03b4 and PI3K\u03b3.", "Pagination": {"StartPage": "123", "MedlinePgn": "123"}, "Abstract": {"AbstractText": ["Phosphatidylinositol 3-kinase (PI3K) is a key regulatory kinase in the PI3K/AKT/mTOR signaling pathway, which is involved in the regulation of cell proliferation, differentiation, apoptosis, and angiogenesis. Class IA PI3K isoforms \u03b3 and \u03b4 share a highly homologous ATP binding site and are distinguished by only a few residues around the binding site. Subtype-selective inhibitors have been proven to have great advantages in tumor treatment. Preliminary studies have obtained PI3K inhibitors bearing a benzimidazole structural motif with a certain selectivity for PI3K\u03b4 and PI3K\u03b3 subtypes. On this basis, we investigated the selective inhibitory mechanism of PI3K\u03b4 and PI3K\u03b3 using four developed inhibitors via molecular docking, molecular dynamics, binding free energy calculations, and residue energy decomposition. This study could provide references for the further development of PI3K-isoform-selective inhibitors."], "CopyrightInformation": "\u00a9 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550025, China."}], "LastName": "Zhang", "ForeName": "Na-Na", "Initials": "NN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy Department of Guizhou Provincial People's Hospital, Guiyang, 55000, China."}], "LastName": "Bai", "ForeName": "Xue", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550025, China."}], "LastName": "Zhao", "ForeName": "Shan-Shan", "Initials": "SS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550025, China."}], "LastName": "Zheng", "ForeName": "Xue-Mei", "Initials": "XM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550025, China."}], "LastName": "Tang", "ForeName": "Lei", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550025, China. ysgpharm@gmc.edu.cn."}], "LastName": "Yang", "ForeName": "Sheng-Gang", "Initials": "SG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550025, China. zjqgmc@163.com."}], "LastName": "Zhang", "ForeName": "Ji-Quan", "Initials": "JQ"}], "GrantList": [{"GrantID": "82060625", "Agency": "National Natural Science Foundation of China", "Country": ""}, {"GrantID": "[2020]1Z073", "Agency": "Natural Science Foundation of Guizhou Province", "Country": ""}, {"GrantID": "gzwjkj2019-1-178", "Agency": "National Science Foundation of Health and Family planning Commission of Guizhou Province", "Country": ""}, {"GrantID": "19NSP073", "Agency": "Young crop project of Guizhou Medical University", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "J Mol Model", "NlmUniqueID": "9806569", "ISSNLinking": "0948-5023"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Benzimidazoles"}, {"RegistryNumber": "0", "NameOfSubstance": "Phosphoinositide-3 Kinase Inhibitors"}, {"RegistryNumber": "E24GX49LD8", "NameOfSubstance": "benzimidazole"}], "MeshHeadingList": [{"QualifierName": ["pharmacology"], "DescriptorName": "Benzimidazoles"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": ["metabolism"], "DescriptorName": "Phosphatidylinositol 3-Kinases"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Phosphoinositide-3 Kinase Inhibitors"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Cantley L (2002) The phosphoinositide 3-kinase pathway. Science 296(5573):1655\u20131657", "ArticleIdList": ["10.1126/science.296.5573.1655"]}, {"Citation": "Leevers SJ, Vanhaesebroeck B (1999) Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 11(2):219\u2013225", "ArticleIdList": ["10.1016/S0955-0674(99)80029-5"]}, {"Citation": "Fresno Vara JA, Casado E, De-Castro J et al (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30(2):193\u2013204", "ArticleIdList": ["10.1016/j.ctrv.2003.07.007"]}, {"Citation": "Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497\u20135510", "ArticleIdList": ["10.1038/onc.2008.245"]}, {"Citation": "Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489\u2013501", "ArticleIdList": ["10.1038/nrc839"]}, {"Citation": "Jackson SP, Schoenwaelder SM (2012) Antithrombotic phosphoinositide 3-kinase \u03b2 inhibitors in humans: a \u2018shear\u2019 delight! J Thromb Haemost 10(10):2123\u20132126", "ArticleIdList": ["10.1111/j.1538-7836.2012.04912.x"]}, {"Citation": "Greenwell IB, Flowers CR, Blum KA et al (2017) Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow. Expert Rev Anticancer Ther 17(3):271\u2013279", "ArticleIdList": ["10.1080/14737140.2017.1285702"]}, {"Citation": "Hirsch E, Morello F, Ciraolo E (2011) Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. Curr Med Chem 18(18):2674\u20132685", "ArticleIdList": ["10.2174/092986711796011193"]}, {"Citation": "Sundstrom TJ, Anderson AC, Wright DL (2009) Inhibitors of phosphoinositide-3-kinase: a structure-based approach to understanding potency and selectivity. Organic & Biomolecular Chemistry 7(1):840\u2013850", "ArticleIdList": ["10.1039/b819067b"]}, {"Citation": "Dwyer CJ, Arhontoulis DC, Rangel RGO et al (2020) Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells. Eur J Immunol 50(9):1386\u20131399", "ArticleIdList": ["10.1002/eji.201948455"]}, {"Citation": "Puri KD, Di Paolo JA, Gold MR (2013) B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies. International Reviews Immunology 32(4):397\u2013427", "ArticleIdList": ["10.3109/08830185.2013.818140"]}, {"Citation": "Costa C, Hirsch E (2010) More than just kinases: the scaffolding function of PI3K. Curr Top Microbiol Immunol 346(1):171\u2013181", "ArticleIdList": ["20563705"]}, {"Citation": "Lee JY, Chiu YH, Asara J et al (2011) Inhibition of PI3K binding to activators by serine phosphorylation of PI3K regulatory subunit p85\u03b1 Src homology-2 domains. Proc Natl Acad Sci 108(34):14157\u201314162", "ArticleIdList": ["10.1073/pnas.1107747108"]}, {"Citation": "Thorpe LM, Yuzugullu H, Zhao JJ (2015) PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nature reviewsCancer 15(1):7\u201324"}, {"Citation": "Knight ZA, Gonzalez B, Feldman ME et al (2006) A pharmacological map of the PI3-K family defines a role for p110\u03b1 in insulin signaling. Cell 125(4):733\u2013747", "ArticleIdList": ["10.1016/j.cell.2006.03.035"]}, {"Citation": "Elmenier FM, Lasheen DS, Abouzid (2019) Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. European Journal of Medicinal Chemistry 183:111718", "ArticleIdList": ["10.1016/j.ejmech.2019.111718"]}, {"Citation": "Zhang JQ, Luo YJ, Xiong YS et al (2016) Design, synthesis, and biological evaluation of substituted pyrimidines as potential phosphatidylinositol 3-kinase (PI3K) inhibitors. J Med Chem 59(15):7268\u20137274", "ArticleIdList": ["10.1021/acs.jmedchem.6b00235"]}, {"Citation": "Wu TT, Guo QQ, Chen ZL, Wang LL, Du Y, Chen R, Mao YH, Yang SG, Huang J, Wang JT, Wang L, Tang L, Zhang JQ (2020) Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors. European Journal of Medicinal Chemistry 204:112637", "ArticleIdList": ["10.1016/j.ejmech.2020.112637"]}, {"Citation": "Dubey A, Kalra S (2013) Computational comparative modeling and visualization for HIV1 and HIV2 proteins via the software SYBYL-X 2.0. International Journal of Scientific and Research Publications 3(10):1\u20136"}, {"Citation": "Laskowski RA, Swindells MB (2011) LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. Journal Chem Inf Model 51(10):2778\u20132786", "ArticleIdList": ["10.1021/ci200227u"]}, {"Citation": "Sanner MF (1999) Python: a programming language for software integration and development. Journal of Molecular Graphics Modeling 17(1):57\u201361"}, {"Citation": "Trott O, Olson AJ, Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455\u2013461", "ArticleIdList": ["19499576", "3041641"]}, {"Citation": "Salomon-Ferrer R, Case DA, Walker RC (2013) An overview of the Amber biomolecular simulation package. WIREs Comput Mol 3(2):198\u2013210", "ArticleIdList": ["10.1002/wcms.1121"]}, {"Citation": "Pemberton OA, Zhang X, Chen Y (2017) Molecular basis of substrate recognition and product release by the Klebsiella pneumoniae Carbapenemase (KPC-2).\u00a0J Med Chem\u00a060(8):3525\u20133530"}, {"Citation": "Folkes AJ, Ahmadi K, Alderton WK et al (2008) The identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51(18):5522\u20135532", "ArticleIdList": ["10.1021/jm800295d"]}, {"Citation": "Berndt A, Miller S, Williams O et al (2010) The p110\u03b4 structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol 6(2):117\u2013124", "ArticleIdList": ["10.1038/nchembio.293"]}, {"Citation": "Zhu JY, Ke K, Xu L, Jin J (2019) Theoretical studies on the selectivity mechanisms of PI3K\u03b4 inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation. J Mol Model 25(8):242", "ArticleIdList": ["10.1007/s00894-019-4129-x"]}, {"Citation": "Esra K, Cyntia T, St\u00e9phane B et al (2017) Derivation of original RESP atomic partial charges for MD simulations of the LDAO surfactant with AMBER: applications to a model of micelle and a fragment of the lipid kinase PI4KA. J Biomol Struct Dyn 35(1):159\u2013181", "ArticleIdList": ["10.1080/07391102.2015.1135822"]}, {"Citation": "Mecklenfeld A, Raabe G (2017) Comparison of RESP and IPolQ-Mod partial charges for solvation free energy calculations of various solute/solvent pairs. J Chem Theory Comput 13(12):6266\u20136274", "ArticleIdList": ["10.1021/acs.jctc.7b00692"]}, {"Citation": "Maier JA, Martinez C, Kasavajhala K et al (2015) ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput 11(8):3696\u20133713", "ArticleIdList": ["10.1021/acs.jctc.5b00255"]}, {"Citation": "Jorgensen WL, Chandrasekhar J, Madura JD et al (1998) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79(2):926\u2013935", "ArticleIdList": ["10.1063/1.445869"]}, {"Citation": "Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25(9):1157\u20131174", "ArticleIdList": ["10.1002/jcc.20035"]}, {"Citation": "Ryckaert JP, Ciccotti G, Berendsen HJC (1977) Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23(3):327\u2013341", "ArticleIdList": ["10.1016/0021-9991(77)90098-5"]}, {"Citation": "Darden T, York D, Pedersen L (1993) Particle mesh Ewald: An N\u00b7log(N) method for Ewald sums in large systems. Journal of Chemical Physics 98(12):10089\u201310092", "ArticleIdList": ["10.1063/1.464397"]}, {"Citation": "Essmann U, Perera L, Berkowitz ML et al (1995) A smooth particle mesh Ewald method. J Chem Phys 103(19):8577\u20138593", "ArticleIdList": ["10.1063/1.470117"]}, {"Citation": "Grand SL, Gotz AW, Walker RC (2013) SPFP: speed without compromise a mixed precision model for GPU accelerated molecular dynamics simulations. Comput Phys Commun 184(7):374\u2013380", "ArticleIdList": ["10.1016/j.cpc.2012.09.022"]}, {"Citation": "Salomon FR, Gotz AW, Poole D, Grand SL, Walker RC (2013) Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald. Journal of Chemical Theory and Computation 9(9):3878\u20133888", "ArticleIdList": ["10.1021/ct400314y"]}, {"Citation": "Wang W, Kollman PA (2000) Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model. J Mol Biol 303(4):567\u2013582", "ArticleIdList": ["10.1006/jmbi.2000.4057"]}, {"Citation": "Chen JZ, Wang JN, Yin B et al (2019) Molecular mechanism of binding selectivity of inhibitors toward BACE1 and BACE2 revealed by multiple short molecular dynamicssimulations and free-energy predictions. ACS Chem Neurosci 10(10):4303\u20134318", "ArticleIdList": ["10.1021/acschemneuro.9b00348"]}, {"Citation": "Wang J, Morin P, Wang W, Kollman PA (2001) Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc 123(22):5221\u20135230", "ArticleIdList": ["10.1021/ja003834q"]}, {"Citation": "Sun H, Li Y, Shen M et al (2014) Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. Physical Chemistry Chemical Physics 16(40):22035\u201322045", "ArticleIdList": ["10.1039/C4CP03179B"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "8", "Day": "27"}, {"Year": "2022", "Month": "3", "Day": "15"}, {"Year": "2022", "Month": "4", "Day": "19", "Hour": "12", "Minute": "3"}, {"Year": "2022", "Month": "4", "Day": "20", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "4", "Day": "22", "Hour": "6", "Minute": "0"}], "PublicationStatus": "epublish", "ArticleIdList": ["35438328", "10.1007/s00894-022-05096-w", "10.1007/s00894-022-05096-w"]}}], "PubmedBookArticle": []}